homepage logo

Medicare limits coverage of $28,000-a-year Alzheimer’s drug

By The Associated Press - | Jan 12, 2022

FILE - The Biogen Inc., headquarters is shown March 11, 2020, in Cambridge, Mass. Medicare says it will limit coverage of a $28,000-a-year Alzheimer’s drug whose benefits have been widely questioned. Tuesday's decision from the Centers for Medicare and Medicaid Services is a major step in the nation’s search for ways to put a fair value on new medicines that offer tantalizing possibilities but come with prohibitive prices. It means that patients taking Biogen’s Aduhelm medication will have to be part of research efforts to assess the drug’s effectiveness in slowing the progression of dementia. The drug has sparked controversy since its approval by the Food and Drug Administration last June, which came against the recommendation of the agency’s outside advisers (AP Photo/Steven Senne, File)


Print Subscriber? Sign Up for Full Access!

Please sign up for as low as 36 cents per day to continue viewing our website.

Digital subscribers receive

  • Unlimited access to all stories from nashuatelegraph.com on your computer, tablet or smart phone.
  • Access nashuatelegraph.com, view our digital edition or use our Full Access apps.
  • Get more information at nashuatelegraph.com/fullaccess
Log In


Join thousands already receiving our daily newsletter.

Are you a paying subscriber to the newspaper? *